DATATRAK Expands Latin American Presence with New CRO Partner STAT Research

CLEVELAND, May 13, 2013 -- DATATRAK International, Inc. (otcqx:DTRK), a leader in developing cloud-based, unified eClinical� technologies and delivering related services for the clinical trials industry, today announced a new partnership with Argentinian CRO STAT Research. STAT Research provides a full range of research services in the Latin American region.

STAT Research CEO Dr. Conrado J. Estol stated: "In the context of a rapidly expanding clinical trial field in the early 2000's, we saw the opportunity to develop a company to become leaders based on our previous research expertise developed over many years in the USA. Our initial focus on CNS soon spanned into many other medical specialties and our group grew solid by incorporating some of the people with most clinical trial experience in the region. Our recent partnership with DATATRAK will add the necessary tools to achieve much more effective and efficient results in an increasingly complex and time-sensitive research environment".

"Our partnership with STAT Research combines the DATATRAK ONE(TM) technology with local industry experts to create a superior solution for advancing clinical trials in Latin America," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "We look forward to assisting STAT Research in leveraging the DATATRAK ONE(TM) clinical research platform to reduce clinical trial costs and accelerate drug development timelines."

The DATATRAK Connect(TM) Partner Program is collaboration between synergic companies to accelerate the drug development process. The program allows for extended service offerings to cover all areas of the drug development process with the goal of reducing study costs and furthering business development objectives.

About STAT ResearchSTAT Research is a medically-driven Contract Research Organization dedicated to providing support services to healthcare institutions, biotechnology and pharmaceutical industries. Founded by an experienced clinical investigator, STAT Research has the capability and expertise to conduct every step of the clinical trial process with the highest quality and efficiency. Operational flexibility, integrity and network are key factors to proactively manage our clients' expectations, guaranteeing successful results through implementation of customized solutions. For more information on STAT Research, see

About DATATRAKDATATRAK International is a worldwide technology and services company delivering unified eClinical� solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services(TM) group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE(TM) software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 15, 2013 announcing its results for the fourth quarter and full year of 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.